# A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

> **NCT07674810** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Sonrotoclax

## Key facts

- **NCT ID:** NCT07674810
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-31
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674810, "A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07674810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*